Ipsen takes on an­oth­er ADC, this time from a Chi­na-based biotech

Ipsen is adding a sec­ond an­ti­body-drug con­ju­gate to its plate.

The French drug­mak­er said Thurs­day that it has inked a glob­al li­cens­ing agree­ment for a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.